Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles D Houslay

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Biochemical Pharmacology|March 12, 2013
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Ryan T Cameron, Ryan G Coleman, Jon P Day, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 31, 2007
Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levelsHannah Murdoch, Shaun Mackie, Daniel M Collins, et al.
Prostate Cancer|July 6, 2019
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion StatusDianne van Strijp, Christiane de Witz, Birthe Heitkötter, et al.
The Biochemical Journal|April 26, 2008
Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKsTian-Rui Xu, George S Baillie, Narinder Bhari, et al.
British Journal of Pharmacology|May 25, 2002
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)Simon J MacKenzie, George S Baillie, Ian McPhee, et al.
Current Biology : CB|May 25, 2010
A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarityBryan Serrels, Emma Sandilands, Alan Serrels, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitorsMatthew D Cullen, York-Fong Cheung, Miles D Houslay, et al.
Cellular Signalling|October 11, 2008
Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA)Daniel M Collins, Hannah Murdoch, Allan J Dunlop, et al.
The Journal of Biological Chemistry|June 18, 2003
Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2Graeme B Bolger, Alexander H Peden, Michael R Steele, et al.
Molecular and Cellular Biology|September 15, 2010
Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4DHyun Wook Kim, Sang Hoon Ha, Mi Nam Lee, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Biochemical Pharmacology|March 12, 2013
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Ryan T Cameron, Ryan G Coleman, Jon P Day, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 31, 2007
Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levelsHannah Murdoch, Shaun Mackie, Daniel M Collins, et al.
Prostate Cancer|July 6, 2019
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion StatusDianne van Strijp, Christiane de Witz, Birthe Heitkötter, et al.
The Biochemical Journal|April 26, 2008
Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKsTian-Rui Xu, George S Baillie, Narinder Bhari, et al.
British Journal of Pharmacology|May 25, 2002
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)Simon J MacKenzie, George S Baillie, Ian McPhee, et al.
Current Biology : CB|May 25, 2010
A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarityBryan Serrels, Emma Sandilands, Alan Serrels, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitorsMatthew D Cullen, York-Fong Cheung, Miles D Houslay, et al.
Cellular Signalling|October 11, 2008
Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA)Daniel M Collins, Hannah Murdoch, Allan J Dunlop, et al.
The Journal of Biological Chemistry|June 18, 2003
Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2Graeme B Bolger, Alexander H Peden, Michael R Steele, et al.
Molecular and Cellular Biology|September 15, 2010
Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4DHyun Wook Kim, Sang Hoon Ha, Mi Nam Lee, et al.
Pageof 14